Sanofi SA (NYSE:SNY) was the recipient of some unusual options trading on Tuesday. Stock investors purchased 1,391 put options on the stock. This represents an increase of approximately 1,946% compared to the average daily volume of 68 put options.
Institutional investors have recently bought and sold shares of the business. Claybrook Capital LLC purchased a new position in shares of Sanofi during the 4th quarter valued at $31,000. Executive Wealth Management LLC bought a new position in shares of Sanofi during the fourth quarter valued at about $34,000. Nkcfo LLC bought a new position in shares of Sanofi during the first quarter valued at about $35,000. Cullen Frost Bankers Inc. bought a new position in shares of Sanofi during the first quarter valued at about $35,000. Finally, Howe & Rusling Inc. bought a new position in shares of Sanofi during the first quarter valued at about $38,000. 7.04% of the stock is currently owned by hedge funds and other institutional investors.
NYSE SNY traded up $0.38 during trading hours on Thursday, hitting $41.95. The company’s stock had a trading volume of 1,870,500 shares, compared to its average volume of 1,226,320. Sanofi has a 52 week low of $40.19 and a 52 week high of $45.62. The stock has a market capitalization of $104.62 billion, a P/E ratio of 13.40, a PEG ratio of 2.41 and a beta of 0.67. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The company’s 50-day moving average price is $42.74.
Separately, TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research note on Friday, June 21st. Eight equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Sanofi currently has an average rating of “Hold” and an average price target of $51.00.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Article: What is a Special Dividend?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.